SL-325
Inflammatory Bowel Disease (IBD)
Phase 2Active
Key Facts
About Shattuck Labs
Shattuck Labs is a clinical-stage biotech with a mission to establish DR3 blockade as a new standard of care in inflammatory and immune-mediated diseases. The company has rapidly advanced its lead asset, SL-325, into Phase 2 development for IBD, leveraging a differentiated receptor-blocking strategy to potentially overcome limitations of existing TL1A-targeting therapies. Its strategy hinges on demonstrating best-in-class remission rates and a favorable immunogenicity profile to capture significant market share in the competitive IBD landscape.
View full company profileTherapeutic Areas
Other Inflammatory Bowel Disease (IBD) Drugs
| Drug | Company | Phase |
|---|---|---|
| HBM2001 | Harbour BioMed | Discovery |
| Metabolite Delivery Platform (Therapeutic Programs) | ClostraBio | Pre-clinical |
| ABO21009 | AboleIIs Pharma | Phase 1 |
| GlyHealth Biomarkers | Avenna | Pre-clinical/Validation |
| GTI-850 | GSNO Therapeutics | Pre-clinical |
| CK-0045 | Cytoki Pharma | Pre-clinical/Research |
| MV-010 | MV BioTherapeutics | Preclinical |
| NM81 | Numab Innovation | Pre-clinical |
| LIAISON® Calprotectin | DiaSorin | Commercial |
| SL-425 | Shattuck Labs | Phase 1 |
| VE202 | PureTech Health | Phase 2 |